ASCO update: Long-term outcomes with nivolumab–relatlimab in advanced melanoma | 7 min

(0 review)
272
students
0
Free

In this expert discussion, Prof Georgina Long AO and Prof Bart Neyns examine the latest five-year follow-up data from the nivolumab–relatlimab clinical trial presented...

Free

ASCO update: Advancing neoadjuvant therapy in resectable Stage III melanoma | 10 min

(0 review)
272
students
0
Free

Join Prof Georgina Long AO and Prof Bart Neyns as they discuss the latest advances in neoadjuvant treatment for resectable Stage III melanoma, presented...

Free

From collaboration to innovation: How multidisciplinary teams and clinical trials are transforming melanoma care | 40 min

(0 review)
281
students
0
Free

In this episode from MIA’s podcast Melanoma Insights for Professionals, our experts explore the critical role of multidisciplinary collaboration in delivering contemporary melanoma care....

Free

Ep. 5: Hype vs Reality: The Future of Immunotherapy | 22 mins

(0 review)
436
students
0
Free

In our final episode of our special vodcast series, Redefining Immunotherapy: Lessons from Melanoma, our experts discuss the future of immunotherapy, separating hype from...

Free

Ep. 4: Melanoma Treatment Strategy: Expert Perspectives | 28 mins

(0 review)
471
students
0
Free

In our fourth episode of our special vodcast series, Redefining Immunotherapy: Lessons from Melanoma, our experts discuss one of the most rapidly evolving areas...

Free

Ep. 3: Immunotherapy Toxicity: Prevention, Early Recognition and Management to Optimise Outcome | 25 mins

(0 review)
538
students
0
Free

In our third episode of our special vodcast series, Redefining Immunotherapy: Lessons from Melanoma, our experts focus on one of the most important challenges...

Free